ecDNA

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022

Retrieved on: 
Wednesday, March 9, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, AACR, American Association for Cancer Research, Therapy, Survival, Oncogene, Cancer, Association, Chromosome, DNA, Rolling circle replication, Radiation, Patient, American Association, Bio, Cell division, Immunotherapy, Growth, Neoplasm, Recurrence, Medical imaging, Vaccine, ecDNA, Boundless Bio, ECDNA, BOUNDLESS BIO

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2022, held in New Orleans and virtually from April 8-13, 2022.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2022, held in New Orleans and virtually from April 8-13, 2022.
  • The in-person poster presentation reveals a novel association between ecDNA bearing tumors and high replication stress, presenting a potential therapeutic strategy for ecDNA-enabled oncogene amplified cancers.
  • ecDNA replicate within cancer cells and, due to their lack of centromeres, can be asymmetrically passed to daughter cells during cell division, leading to focal gene amplification and copy number heterogeneity in cancer.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

Boundless Bio Presents Data on Extrachromosomal DNA (ecDNA) Driven Resistance to KRASG12C Inhibitors at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Retrieved on: 
Thursday, October 7, 2021
Oncology, Health, Genetics, Research, Science, Biotechnology, Neoplasm, Harvard Medical School, EGFR, George M. Low Center for Industrial Innovation, Rolling circle replication, Fluorescence, Chromosome, Conference, Poster, Survival, FISH, Growth, Cancer, In situ hybridization, Dana–Farber Cancer Institute, KRAS, Kinetics, Radiation, Assistant, Bio, Immunotherapy, AACR, FGFR, Therapy, Cell division, DNA, Recurrence, Oncogene, Patient, Clinical trial, NGS, Colorectal cancer, Vaccine, Pharmaceutical industry, Medical imaging, ecDNA, Boundless Bio, ECDNA, BOUNDLESS BIO

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in aggressive cancers, today will present a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in aggressive cancers, today will present a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
  • The poster, LBA005: Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors , is available to registered attendees starting at 9AM EST today.
  • ecDNA driven oncogene copy number amplifications, a mechanism that is distinct from second site mutations, is a frequent cause of resistance in cancer cells.
  • Boundless Bio, in collaboration with the Dana-Farber Cancer Institute and Mirati Therapeutics, has shown that, in colorectal patients treated with KRASG12C inhibitors, ecDNA based amplification played an important role in resistance to KRASG12C inhibitor therapy.

Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Retrieved on: 
Wednesday, September 22, 2021
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Rolling circle replication, Cancer, Radiation, Dana–Farber Cancer Institute, Recurrence, Therapy, Conference, DNA, Dana, FDA, Patient, AACR, Bio, Immunotherapy, Cell division, Colorectal cancer, Survival, Oncogene, Pharmaceutical industry, Vaccine, ecDNA, Boundless Bio, ECDNA, BOUNDLESS BIO

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.
  • These findings support previous Boundless Bio published work that ecDNA is an important underlying cause of cancer resistance and reinforces the critical need for novel therapeutic strategies to address ecDNA enabled cancers.
  • ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)

Retrieved on: 
Wednesday, April 28, 2021
Biotechnology, Health, Oncology, Clinical trials, Boundless, Cancer, Boundless Bio, ecDNA, Boundless Bio’s Spyglass™ Platform, BOUNDLESS BIO, ECDNA, BOUNDLESS BIO’S SPYGLASS™ PLATFORM

b'Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing.

Key Points: 
  • b'Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing.
  • In conjunction with the financing, Jakob Loven, Ph.D., Partner at Nextech Invest, will join the Boundless Bio Board of Directors.\n\xe2\x80\x9cBoundless Bio has made tremendous progress since launching in 2019,\xe2\x80\x9d said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
  • From these efforts, we have discovered and validated three ecDNA-essential targets and have initiated drug discovery against each.
  • \xe2\x80\x9cecDNA is a transformative new area of cancer biology, and Boundless Bio is the clear leader in the rapidly emerging field.

Boundless Bio Presents Data on the Role of Extrachromosomal DNA (ecDNA) in Mediating Resistance to Targeted Therapies at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Saturday, April 10, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Cancer, Medicine, Oncology, Clinical medicine, Targeted therapy, Health, Extrachromosomal circular DNA, ecDNA, Boundless Bio

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today will present data at the 2021 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today will present data at the 2021 American Association for Cancer Research (AACR) Annual Meeting.
  • This study provides rationale for why patients with oncogene amplified tumors have not benefited from targeted therapies.
  • The study set out to understand the role of ecDNA in facilitating poor responses to targeted therapies in gene amplified cancer.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Wednesday, March 31, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, DNA, Extrachromosomal DNA, Cancer, Oncology, Branches of biology, Medical specialties, Health, Medical genetics, Carcinogenesis, ecDNA, Boundless Bio

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.
  • ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer.
  • They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Announces Poster Presentation at the 2020 American Society of Human Genetics (ASHG) Virtual Annual Meeting

Retrieved on: 
Wednesday, October 21, 2020
Biotechnology, General Health, Health, Genetics, Oncology, DNA, Medicine, Health, Clinical medicine, Carcinogenesis, Oncology, Extrachromosomal DNA, Draft:Boundless Bio, Cancer, Oncogene, Tumour heterogeneity, Extrachromosomal circular DNA, ecDNA, Boundless Bio

Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.

Key Points: 
  • Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.
  • ecDNA rapidly replicate within cancer cells, causing high numbers of oncogene copies and can be passed to daughter cells asymmetrically during cell division, driving tumor heterogeneity.
  • They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Announces Publication in Nature Genetics Detailing the Association Between Extrachromosomal DNA-Based Oncogene Amplification and Poor Cancer Outcomes

Retrieved on: 
Monday, August 17, 2020
Genetics, Health, Oncology, DNA, Draft:Boundless Bio, Branches of biology, Medical genetics, Extrachromosomal DNA, Biology, Applied genetics, Biotechnology, Cancer, Oncogenomics, ecDNA, Boundless Bio, Boundless Bio’s Spyglass™ Platform

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced research published in the journal Nature Genetics that demonstrates that ecDNA-based oncogene amplification drives poor outcomes for patients across many cancer types.

Key Points: 
  • Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced research published in the journal Nature Genetics that demonstrates that ecDNA-based oncogene amplification drives poor outcomes for patients across many cancer types.
  • Ludwig Professor of Cancer Genomics and Genetics, Stanford University; and Roel Verhaak, Ph.D., Professor and Associate Director of Computational Biology, The Jackson Laboratory.
  • In addition, patients whose cancers carried ecDNA had significantly shorter survival, even when controlled for tissue type, than patients whose cancers were not driven by ecDNA-based oncogene amplification.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Scientific Co-Founder Paul Mischel to Present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

Retrieved on: 
Tuesday, June 16, 2020
Oncology, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Causes of death, Extrachromosomal DNA, Health, Medicine, Paul Mischel, Cancer, DNA, Oncogene, Extrachromosomal circular DNA, ecDNA, Boundless Bio

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that scientific co-founder, Paul Mischel, M.D., will be lecturing on the foundational role that ecDNA plays in driving resistance to standard of care therapies at the American Association for Cancer Research (AACR) Virtual Annual Meeting II , held June 22-24, 2020.

Key Points: 
  • Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that scientific co-founder, Paul Mischel, M.D., will be lecturing on the foundational role that ecDNA plays in driving resistance to standard of care therapies at the American Association for Cancer Research (AACR) Virtual Annual Meeting II , held June 22-24, 2020.
  • Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes that are located outside cells chromosomes and can make many copies of themselves.
  • ecDNA rapidly replicate within cancer cells, causing high numbers of oncogene copies, a trait that can be passed to daughter cells in asymmetric ways during cell division.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Presents Data Assessing the Relationship Between Extrachromosomal DNA and Biomarker Signatures Associated with Response to Checkpoint Inhibitors in Gastric Cancer at the 2020 ASCO Virtual Annual Meeting

Retrieved on: 
Friday, May 29, 2020
Oncology, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, DNA, Biotechnology, Extrachromosomal DNA, Cancer, Biology, ecDNA, Boundless Bio

The ecDNA-positive subtype also had lower PD-L1 expression than all the other molecular subtypes but the GS and CIN subtypes.

Key Points: 
  • The ecDNA-positive subtype also had lower PD-L1 expression than all the other molecular subtypes but the GS and CIN subtypes.
  • Boundless Bio is developing novel therapeutic strategies directed to mechanisms critical for ecDNA function in cancer.
  • Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells chromosomes and can make many copies of themselves.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.